Status
Conditions
Treatments
About
To investigate the impact of canagliflozin on secretion of gut hormones, in particular glucagon-like peptide 1 (GLP-1) in gastric bypass operated patients.
Full description
Glucose is a potent stimulus for GLP-1 secretion after gastric bypass surgery and the SGLT-1 transporter appears to be crucial for this response. The study will investigate the effects of SGLT-1/SGLT-2 inhibition (by canagliflozin) on secretion of GLP-1 and other gut hormones after gastric bypass surgery.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
•Uncomplicated gastric bypass surgery performed minimum 12 months prior to study
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
10 participants in 2 patient groups
Loading...
Central trial contact
Sten Madsbad, Professor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal